Lung Cancer

The FDA has granted an accelerated approval to osimertinib for patients with advanced EGFR T790M mutation positive non–small cell lung cancer following prior therapy on a prior EGFR TKI.

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.

Clinical trial designs are transforming dramatically in order to expedite the discovery and validation of new predictive biomarkers for patients with non–small cell lung cancer and other types of solid tumors.

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

The impact upon cancer care, made by Paul Bunn, MD, extends far beyond the programs he helped build in Colorado.

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Acting 3 months ahead of schedule, the FDA approved nivolumab for patients with nonsquamous non–small cell lung cancer previously treated with platinum-based chemotherapy.

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

David S. Ettinger, MD, discusses recent advancements in NSCLC, specifically with immunotherapy, and explains challenges that have stemmed from these developments.

The FDA approved pembrolizumab (Keytruda) as a treatment for patients with pretreated advanced non­–small cell lung cancer across all histologies whose tumors express PD-L1.